Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study.
Saved in:
| Title: | Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study. |
|---|---|
| Authors: | Izaaryene, Jean1 (AUTHOR) izaaryenej@ipc.unicancer.fr, Grange, Rémi2 (AUTHOR), Habouzit, Vincent2 (AUTHOR), Grange, Sylvain2 (AUTHOR), Orsini, Bastien3 (AUTHOR), Dassa, Michael1 (AUTHOR), Daidj, Nassima1 (AUTHOR), Thierry, Louis1 (AUTHOR), Ferre, Marjorie1 (AUTHOR), Phelip, Jean Marc2 (AUTHOR), Lelong, Bernard4 (AUTHOR), De Chaisemartin, Cécile4 (AUTHOR), Mitry, Emmanuel5 (AUTHOR), Piana, Gilles1 (AUTHOR) |
| Source: | European Radiology. Jun2025, Vol. 35 Issue 6, p3282-3293. 12p. |
| Subjects: | Colorectal cancer, Cryosurgery, Surgical complications, Retrospective studies, Cancer patients |
| Abstract: | Objectives: To evaluate the oncological efficacy and complications of cryoablation (CA) in treating lung metastases from colorectal cancer (CRC) at the lung periphery. Materials and methods: The inclusion criteria for this bicenter retrospective study included patients with histologically confirmed CRC, with radiologically confirmed lung metastases at the periphery of the lung (distance of less than or equal to 2 cm from the costal, diaphragmatic, or cervical pleura) treated with CA between January 2017 and June 2022. Patients with intra-parenchymal metastases or metastases close to the mediastinal pleura and patients without follow-up were excluded. Results: Seventy-three patients were included (median age: 69 years, range 47.0–83.0; 38 males, 52.0%) with 113 metastases and 89 procedures. Technical success was achieved in all procedures. During follow-up (median 22 months), on a per metastasis basis, local recurrence occurred for 8/113 (7%) of the metastases in 7 patients at a median time of 19 months; 7 had concomitant distant recurrence. Local progression-free survival rates were 95% at 1 year and 89% at 2, 3, and 4 years. Distant progression occurred in 41/73 (56.2%) patients, significantly associated with a history of liver metastasis and synchronous lung metastasis (p < 0.05). The median chemotherapy-free survival was 14 (IQR (5.0–21.5)) months. Complications were predominantly mild or moderate, with a low incidence of severe complications. Conclusion: CA demonstrates high rate of local control and appears well-tolerated in the treatment of peripheral lung metastases from CRC. The procedure offers a viable therapeutic option, allowing patients a significant period without chemotherapy. Key Points: QuestionDespite its advantages over surgery, data on cryoablation of metastases from colorectal cancer at the periphery of the lung are lacking. FindingsCryoablation enabled very good local control, with local progression-free survival rates of 95% at 1 year and 89% at 2, 3, and 4 years. Clinical relevanceCryoablation is an effective treatment for local tumor control of lung metastases from colorectal cancer at the periphery of the lung. The treatment is well tolerated and can provide patients with substantial relief from chemotherapy. [ABSTRACT FROM AUTHOR] |
| Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objectives: To evaluate the oncological efficacy and complications of cryoablation (CA) in treating lung metastases from colorectal cancer (CRC) at the lung periphery. Materials and methods: The inclusion criteria for this bicenter retrospective study included patients with histologically confirmed CRC, with radiologically confirmed lung metastases at the periphery of the lung (distance of less than or equal to 2 cm from the costal, diaphragmatic, or cervical pleura) treated with CA between January 2017 and June 2022. Patients with intra-parenchymal metastases or metastases close to the mediastinal pleura and patients without follow-up were excluded. Results: Seventy-three patients were included (median age: 69 years, range 47.0–83.0; 38 males, 52.0%) with 113 metastases and 89 procedures. Technical success was achieved in all procedures. During follow-up (median 22 months), on a per metastasis basis, local recurrence occurred for 8/113 (7%) of the metastases in 7 patients at a median time of 19 months; 7 had concomitant distant recurrence. Local progression-free survival rates were 95% at 1 year and 89% at 2, 3, and 4 years. Distant progression occurred in 41/73 (56.2%) patients, significantly associated with a history of liver metastasis and synchronous lung metastasis (p < 0.05). The median chemotherapy-free survival was 14 (IQR (5.0–21.5)) months. Complications were predominantly mild or moderate, with a low incidence of severe complications. Conclusion: CA demonstrates high rate of local control and appears well-tolerated in the treatment of peripheral lung metastases from CRC. The procedure offers a viable therapeutic option, allowing patients a significant period without chemotherapy. Key Points: QuestionDespite its advantages over surgery, data on cryoablation of metastases from colorectal cancer at the periphery of the lung are lacking. FindingsCryoablation enabled very good local control, with local progression-free survival rates of 95% at 1 year and 89% at 2, 3, and 4 years. Clinical relevanceCryoablation is an effective treatment for local tumor control of lung metastases from colorectal cancer at the periphery of the lung. The treatment is well tolerated and can provide patients with substantial relief from chemotherapy. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 09387994 |
| DOI: | 10.1007/s00330-024-11153-0 |
